Misplaced Pages

:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Tefibazumab: Difference between pages - Misplaced Pages

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Difference between pages)
Page 1
Page 2
Content deleted Content addedVisualWikitext
Revision as of 18:48, 9 January 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 466156509 of page Tefibazumab for the Chem/Drugbox validation project (updated: 'CAS_number').  Latest revision as of 20:57, 1 December 2023 edit Buidhe (talk | contribs)Autopatrolled, Extended confirmed users, Page movers, File movers, Mass message senders, New page reviewers, Pending changes reviewers, Template editors136,053 editsm Moving from Category:Experimental drugs to Category:Experimental monoclonal antibodies using Cat-a-lot 
Line 1: Line 1:
{{Short description|Monoclonal antibody}}
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}}
{{Drugbox {{Drugbox
| Verifiedfields = changed | Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 450331798 | verifiedrevid = 470478505
| image = | image =
<!-- Monoclonal antibody data -->

<!--Monoclonal antibody data-->
| type = mab | type = mab
| mab_type = mab | mab_type = mab
| source = zu/o | source = zu/o
| target = ] | target = ]
<!-- Clinical data -->

| tradename = Aurexis
<!--Clinical data-->
| tradename =
| pregnancy_AU = | pregnancy_AU =
| pregnancy_US = | pregnancy_US =
Line 22: Line 21:
| legal_status = | legal_status =
| routes_of_administration = | routes_of_administration =
<!-- Pharmacokinetic data -->

<!--Pharmacokinetic data-->
| bioavailability = | bioavailability =
| protein_bound = | protein_bound =
Line 29: Line 27:
| elimination_half-life = | elimination_half-life =
| excretion = | excretion =
<!-- Identifiers -->

| CAS_number_Ref = {{cascite|changed|CAS}}
<!--Identifiers-->
| CAS_number = 521079-87-8
| CAS_number_Ref = {{cascite|correct|??}}
| UNII_Ref = {{fdacite|changed|FDA}}
| CAS_number = <!-- blanked - oldvalue: 521079-87-8 -->
| UNII = SBO7Q9G95R
| ATC_prefix = none | ATC_prefix = none
| ATC_suffix = | ATC_suffix =
Line 41: Line 40:
| KEGG = D06054 | KEGG = D06054
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = NA | ChemSpiderID = none
<!-- Chemical data -->

| C=6548 | H=10122 | N=1730 | O=2034 | S=44
<!--Chemical data-->
| C=6548 | H=10122 | N=1730 | O=2034 | S=44
| molecular_weight = 147.590 ]
}} }}

'''Tefibazumab''' (named '''Aurexis''' but not approved) is a ] for the treatment of severe infections with '']''. Possible indications include the treatment of ''S. aureus'' in a phase 2a patients with ]<ref>{{ClinicalTrialsGov|NCT00198289|Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs}}</ref> and of ].<ref>{{cite journal | vauthors = Pan A, Lorenzotti S, Zoncada A | title = Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection | journal = Recent Patents on Anti-Infective Drug Discovery | volume = 3 | issue = 1 | pages = 10–33 | date = January 2008 | pmid = 18221183 | doi = 10.2174/157489108783413173 }}</ref>

It was developed by Inhibitex.<ref name="pmid17078388">{{cite journal | vauthors = John JF | title = Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection | journal = Current Opinion in Molecular Therapeutics | volume = 8 | issue = 5 | pages = 455–60 | date = October 2006 | pmid = 17078388 }}</ref>

== See also ==
* ] (microbial surface components recognizing adhesive matrix molecules)

== References ==
{{reflist}}

{{Monoclonals for infectious disease and toxins}}

]
]
{{antiinfective-drug-stub}}
{{monoclonal-antibody-stub}}